Otsuka Chemical has acquired Astellas Pharma’s cefixime business. Through this agreement, Otsuka will supply the active pharmaceutical ingredient (API) to licensees abroad together with assets such as contracts belonging to the licensing company and the commercial brand. This deal segnals the entry of the company into the API business, which strengthens the business related to antibiotics integrated from intermediaries to API.   Cefixime developed by Astellas Pharma is a third-generation cephalo...